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Abstract 
 SCID-X1 is a profound deficiency of T-, B- and NK- cell immunity caused by mutations in 
IL2RG encoding the common chain (γc) of several interleukin receptors.  Gamma-retroviral 
(γRV) gene therapy of SCID-X1 infants without conditioning restores T-cell immunity 
without B- or NK-cell correction, but similar treatment fails in older SCID-X1 children. 
Here, we employed a novel lentivirus gene therapy approach to treat 5 SCID-X1 patients 
with persistent immune dysfunction despite haploidentical-hematopoietic stem cell transplant 
(HSCT) in infancy.  Follow-up data from 2 older patients demonstrates that lentivirus vector 
γc transduced autologous HSC gene therapy following non-myeloablative busulfan 
conditioning achieves selective expansion of gene marked T-, NK- and B-cells that is 
associated with sustained restoration of humoral responses to immunization and clinical 
improvement at 2-3 years after treatment.  Similar gene marking levels have been achieved 
in 3 younger patients, albeit with only 6-9 months of follow-up.  Lentiviral-gene therapy 
with reduced-intensity conditioning appears safe and can restore humoral immune function 
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to post-haploidentical transplant older patients with SCID-X1. (163 words) 
 
One Sentence Summary: Lentiviral gene therapy with conditioning achieves multi-
lineage marking and humoral reconstitution in older SCID-X1 patients post haploidentical HSCT. 
 
Introduction: 
Haploidentical hematopoietic stem cell transplantation (HSCT) without conditioning for 
treatment of SCID-X1 infants achieves ≥70% long-term survival. However, while donor T-cells 
engraft and are functional, ~2/3 of such patients lack B- and NK-cell reconstitution, which may 
ultimately lead to progressive clinical deterioration (1-3). Gamma-retroviral (γRV) gene therapy 
without conditioning effectively corrects the T-cell lineage with no transduced B- or NK- cells 
in SCID-X1 infants (4), but fails in post-haploidentical HSCT older children, possibly due to 
age- 
related thymic damage (5, 6). 
Leukemias occurred in γRV-gene therapy for SCID-X1, Wiskott-Aldrich syndrome (WAS) and 
Chronic Granulomatous Disease (CGD) attributable to preferential integration near oncogenes 
(7-10).  Adding a self-inactivating element (SIN) in γRV gene therapy for SCID-X1 infants 
resulted in a similar integration pattern as earlier γRV trials although less clustering near 
oncogenes is observed at 38 months follow-up (11). Unlike murine gRV, lentivirus vectors (LV) 
do not preferentially integrate near enhancers and promoters and successful SIN-LV gene 
therapy employing marrow conditioning of WAS and Metachromatic Leukodystrophy (MLD) 
(12, 13) suggests that SIN-LV may be applicable to SCID-X1.  
In this study, we used a codon-optimized SIN-LV (Cl20-i4-EF1a HγcOPT) where the 
elongation factor 1α (EF1α) core promoter element drives production of γc with an additional 
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safety feature of a 400-bp chicken β-globin chromatin insulator element (cHS4) (Fig. S10) (14, 
15).  Pre-clinical studies demonstrated safety and efficacy in animal models (16, 17). We report 
successful SIN-LV gene therapy of older SCID-X1 patients who had significant immune and 
functional problems following previous haploidentical HSCT. Novel features of our clinical 
trial include first use of SIN-LV to treat SCID-X1, first use of busulfan conditioning for gene 
therapy of SCID-X1, and first use in patients of SIN-LV manufactured from a stable LV 
producer cell line (18). Reduced intensity conditioning has proven beneficial in gene therapy 
for adenosine deaminase deficient(ADA)-SCID including the development of gene-marked B-
and NK-cells (19, 20) . 
 
Results: 
Patient characteristics 
Five male patients with SCID-X1, aged 23, 22, 7, 16 and 10 years (P1-P5), with persistent 
disease following one or more haploidentical HSCT (Table 1) were treated in a phase I/II 
clinical trial. This report describes the course of P1 and P2 through 36 months and 24 months 
and P3-P5 through 9, 6, and 6 months following autologous SIN-LV (EF1a-hgcOPT)-
transduced CD34+ HSC transplant, with a total of 6mg busulfan /kg i.v. pre-conditioning. 
Busulfan levels were drawn on day 1 after the first 3mg busulfan /kg dose, and ranged from 2519.6 to 
4528.9 min*umol/L (Table 1). Results of the AUC levels were not available in time to allow dose 
adjustment. The patients recovered their absolute cell numbers without need of blood product 
support for discharge within one month (Fig. S2) and monitored per Protocol Schedule (Table 
S1). 
 
Self-inactivating Lentivector from Stable Producer and HSC Transduction 
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The lentivector (LV) used in the study is self-inactivating (SIN) and utilizes an EF1α promotor to drive 
a codon-optimized human γc cDNA, flanked by a 400bp chicken insulator (14, 15). Unlike γRV that is 
produced by stable cell lines, LV used for clinical gene therapy trials thus far rely on transient, four-
plasmid transfections of packaging cells. The quantity of high-titer clinical grade vector produced using 
this approach is generally insufficient to treat larger (adult) subjects.  In contrast, the stable SIN- EF1a-
hγcOPT producer can make up to 150 liters of vector at 5 × 106 Infectious Units (i.u.)/ml for each 
production run.  The downstream process and quality controls resulted in vector at 4-7 × 108 i.u. /ml as 
previously described (15). 
CD34+ HSCs were mobilized with G-CSF and pleraxifor (21) and were collected by apheresis and 
cryopreserved.  Autologous HSCs (1-2 × 107 CD34+ HSC/kg) were pre-stimulated with stem cell 
factor, FLT-3L, and thrombopoietin (100ng/ml) for 16 hours before two daily 7-hour transductions at a 
MOI of 100-150 with vector concentration ~30% of culture volume (Fig. S1). On day 3, transduced 
cells were washed and infused following confirmation of quality and safety criteria.  Between 17.0 to 
57.7% of colonies derived from the bulk transduced cells were gene marked (Table 1). 
Multi-lineage Gene Marking and Immune Reconstitution following gene therapy 
Peripheral blood cells from patients were purified by density fractionation and magnetic bead-
based immunoselection into lineages including polymorphonuclear cells (PMN), CD14, CD3, 
CD19, and NK cells (see (SM&M)). Gene marking was monitored over 2-3 years in P1 and P2 
and demonstrated an increase in gene marking for all lineages tested (Fig.1A). Myeloid 
marking in PMN and CD14+ cells appeared by 2 weeks and stabilized by 6 months at 0.08-0.1 
vector copy number (VCN) per cell in both P1 and P2. Vector marking of B- and NK-cells 
appeared later but the levels exceeded that of myeloid cells at 0.30-0.40 and 0.56-0.77 VCN, 
respectively. T-cell marking lagged until 5-6 months post-treatment but steadily increased to 
0.13-0.57 VCN.  CD14+ and B-cell marking occurs early in all five patients, particularly in P4 
and P5 who received relatively larger doses of corrected HSC (Fig. 1B). Importantly, gene 
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marking was also evident in circulating peripheral blood CD34+ HSC from P1 and P2 at 1 year 
and at 4 months, respectively, approaching the myeloid levels (Fig. 1A). 
 
Emergence of Gene-corrected autologous T-cells  
To preserve donor T-cells, patients did not receive T-cell depleting agents. Autologous T-cells, 
identified by microsatellite DNA fingerprinting chimerism analysis, increased about 10 
months post-treatment (Fig. 1C) corresponding to the increase in T-cell vector marking and T- 
cell numbers in P1 (Fig. 1D). In P2, increased gene marking in T-cells with concomitant 
increased autologous T-cell chimerism without significant changes in his total number of T-cells 
likely reflected a replacement of donor T-cells by the autologous gene-corrected T-cells (Fig. 
1D). A possible explanation for the relative survival advantage of autologous gene-corrected T-
cells may be better cross-talk between autologous T-cells with the other immune cells, or 
constitutive expression of γc, although no increases in expression of γc or its downstream 
signaling component JAK3 was found in earlier gene therapy trials (22). T-cell receptor excision 
circles (TRECs), a measure of thymic-derived T-cells, increased from <25 TREC/µg to 90-120 
TREC/µg DNA in both P1 and P2, where the lower limit of normal range for this assay is 75 
TREC/µg DNA (Fig. S4). In vitro T-cell functional responses to mitogenic stimulation were 
significantly improved following treatment (Fig. 2A). Due to a lag in the appearance of gene 
marked immune cells, a less substantial increase is expected in P3-5 at this early stage (Fig. 
S5).  
 
Gene-corrected Transitional B-cells and Humoral Reconstitution 
Gene­corrected B­cells emigrating from bone marrow first appear in peripheral blood as 
immature/transitional T1 (CD10++/CD21lo) B­cells, which increased in P3 from 2.6% pre­ 
treatment to 25% at 8 weeks post treatment (Fig. 2B, C), subsequently differentiating into 
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transitional T2/T3 (CD10+/CD21hi) B­cells with a concomitant decrease in T1 being noted from 
9 weeks (Fig. 3B, C), consistent with previously described phenotypes (23)(14). The derivation 
of T1, T2/3 B­cells was confirmed by gene marking in sorted B­cell subsets, with VCN in 
T1>T2/3>Naïve> myeloid for P3-5 (Fig. 2F). Longer follow up in P1 and P2 demonstrated 
functional correction in B-cells with class-switching to IgG+CD27+memory B- cells (Fig. S6) 
and normal IgG (Fig. 2D).  In all patients, serum IgM increased starting about 3 months 
post­therapy  (Fig 2E).  Interpretation of IgG production in patients receiving IgG supplements is 
challenging, although IgM levels are not affected by IgG supplementation. Along with the early 
appearance of gene-marked B-cells, serum IgM levels also increased early with the greatest 
increases seen in P1 and P4. These subjects had largest proportion of vector positive colonies 
from the CFU assay performed on the bulk transduced HSCs, especially P4 who also achieved 
the highest level of busulfan AUC and received one of the most CD34+ cells. A diagnostic 
workup for monoclonal gammopathy in P1 (including PET-CT) was negative and the increased 
IgM levels spontaneously declined as the IgG levels increased.  Response to IL­21 was 
demonstrated in vitro with peripheral blood cells from P1 at 6 months post­therapy (Fig. 3A). 
ELISpot analysis of P1 before and after vaccination with the 2013 Flu­vaccine (at 12 months 
post­therapy) demonstrated significantly increased vaccine­specific IgG+ B­cell frequencies, as 
well as the total number of IgG+ B­cells, thus confirming reconstitution of humoral immunity 
(Fig. 3B). Vaccine­ induced responses to polio, diphtheria, tetanus, hemophilus were observed 
in P1 and P2, including a robust response in P1 to anti­rabies vaccination, an FDA­approved 
antigen, with anti­rabies titer of 11.3 International Units/ml (>0.5 IU/mL represents acceptable 
response). Of note, the improved B-cell responses may be attributable to interaction of the gene-
corrected B-cells with either the donor T-cells or the autologous gene-corrected T-cells.  
Gene marking in CD3-CD56+ NK-cells also appeared by 2 months and doubled by 15 months for 
P2 (Fig. 1A). Post-therapy NK-cells had features of mature NK-cells similar to those observed in 
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healthy controls (Fig. S7). The increase in P2’s NK cell numbers coincided with shrinkage of 
warts (Fig. 4A). 
 
Clinical Benefits 
For P2, extensive molluscum contagiosum and disfiguring warts on both hands improved post-
gene therapy (Fig. 4A). Chronic (>2 years prior to treatment) norovirus infections in P1 and P2 
cleared within 21 months of therapy and severe protein-losing enteropathy resolved with 
normalization of albumin, and weight gain indicative of an improved nutritional state (Fig. 4B, 
4C). P2 entered the study with bronchiectasis with irreversible airway damage (Fig. S8) 
complicated by severely impaired pulmonary function (<40% of normal).  Worsening lung 
disease led to a fatal pulmonary bleed at 27 months post-gene therapy. 
 
Vector integration clonality analysis (VISA) 
VISA of sorted blood lineages in P1 and P2, using previously described methods (24, 25) 
identified 333,822 integration events, of which 38% were unique integration sites and most 
clones comprising <1% of total sites (Fig. 5A). Using the Chao estimator for species richness, the 
greatest diversity was observed in B-cells, followed by myeloid cells, then T- and NK-cells 
(Table S2)(26). In addition to the diversity of the integration site repertoire, our goal is to be able 
to detect clone(s) that may undergo any significant expansion.  Oligoclonality index (OCI)(27) 
may overestimate polyclonality in situations of limited library size or sample material, further 
described in SM&M. To facilitate comparison of clonal expansion between samples, we 
determined the number of unique clones comprising the top 50% of the total clones, the Unique 
Clone Index (UC50)  (Fig 5A)(SM&M).  UC50 for NK-cells suggests a more limited diversity with 
79 clones comprising half of all NK-cells for P1 at 30m, and 7 for P2 at 24m (Fig. 5A). 
Quantitative ddPCR surveillance of the most abundant clones revealed the fluctuations in clonal 
abundance within each lineage (Fig. 5B).  Although individual clones transiently increased in 
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abundance, in particular those possessing integrations near the TNFSF12 and the PIM1 gene, 
these declined over time.  
 
Vector Integration Site Distribution 
A comparison of P1 and P2’s VISA datasets to an in vitro LV-transduced CD34+ cell library 
dataset (259,648 unique sites) mapped across the human genome (Fig. 6A) confirms LV’s 
preferential targeting of actively expressed genes and gene-dense regions (79% within genes 
versus 39% for random control) (24, 25)(discussed further in SM&M). Also evident from this 
comparison is that the in vivo IS repertoire is remarkably similar to that of the input clones, 
highlighting the dominant effect of the vector-specific integration preferences retained in in vivo 
patient samples independent of disease or therapeutic gene (WAS, MLD and ALD) transferred 
(12, 13). A comparison of shared integration sites between different lineages at different time 
points, or Similarity Index shows highly variable IS in myeloid cells, consistent with the 
increased cell turnover rates in myeloid compared with T-cells (Fig. S9). 
Many of the integration sites in our patient samples are shared with the common integration sites 
(CIS) in the lentiviral Wiskott-Aldrich Syndrome trial (12) although they do not appear to be 
enriched compared to the initial in vitro CD34+ cell library, suggesting a lack of selective in vivo 
expansion. In contrast, HMGA2 has multiple unique integrations, most of which are in the same 
orientation, especially in intron 3 (Fig. 5C).  Although over 38-fold enrichment in HMGA2 
contribution is observed in vivo, the overall contribution from HMGA2 integrant clones remained 
very low in all gene-marked cells (~1%), with no significant expansion of any single clone. In the 
β-thalassemia study, a single HMGA2 integrant clone was highly expanded due to an alternative 
splice acceptor created by the unstable 2 x 250bp cHS4 insulator core that resulted in the 
overexpression of a truncated and more stable HGMA2 protein (29). Using primers targeting the 
flanking insulators (Fig.S10), we confirmed the integrity of our transgene sequence around the 
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insulators, without any evidence for rearrangement. To assess for potential biological effects of 
the low level expansion of HMGA2 integrant clones, the expression level of HMGA2 in different 
lineages of PB from P1 and P2 was determined using ddPCR assays for the 5’ (exon 3, before 
integration sites) and 3’ (exon 4/5, after integration site).  Expression of HMGA2 in all cell 
lineages was low (data not shown) and the ratio of the 5’assay/3’assay was close to 1, suggesting 
no overexpression of a truncated form of HMGA2. 
 
Discussion: 
 
This study describes the first successful SIN-LV gene therapy with low-dose busulfan 
conditioning of older SCID-X1 patients who had failed previous HSCT. In P1 and P2, with ≥2 
years follow-up, significant stable gene marking in multiple hematopoietic lineages coincided 
with reconstitution of humoral immunity, specific vaccine responses and marked clinical 
improvement, in contrast to restricted T-cell marking in prior mgRV gene therapy trials without 
conditioning (4). This was also the first use of SIN-LV made by a stable producer cell line, 
GPRG-γc, with multiple copies of self-inactivating vector genomes generated by a concatemeric 
array transfection technique (18) that permitted production of high-titer vector (>108 IU/ml) 
sufficient to treat >1 × 109 or 2 × 107/kg cells for each patient (17). Despite reported improved 
outcomes with myeloid conditioning in ADA-SCID and Wiskott-Aldrich syndrome gene 
therapy trials, particularly with regards to B- or NK-cell reconstitution, no myelo-conditioning 
has been used in SCID-X1 to date (19, 30).  Significant multi-lineage marking in this study 
underscores the importance of myeloid conditioning to improve engraftment in SCID-X1, 
although lentivector likely also targets HSC more efficiently, since mγRV gene therapy with 
busulfan conditioning in Chronic Granulomatous Disease (18) and WAS (19) did not result in 
significant B-cell gene marking.  
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Humoral reconstitution in P1 and P2 corresponded with the eradication of chronic norovirus in P1 
and P2, a poorly appreciated medical problem in SCID-X1 patients with incomplete immune 
reconstitution following prior haplo-HSCT without conditioning. Despite minimal diarrhea, 
chronic norovirus infection in these patients can result in a protein-losing enteropathy, 
electrolyte-, mineral-and vitamin-losses and subsequent nutritional and growth failure with 
endoscopic appearance of Celiac-like flat or blunted villi. It is interesting that the gene-corrected 
B-cells were able to eradicate the norovirus while both oral IgG (used by some to treat chronic 
norovirus) and IV IgG failed, suggesting a potentially unique role for gut lamina propria B-cells 
in the control of norovirus.  
 
We also report the first significant gene marking and correction of NK-cells in SCID-X1 
following gene therapy with substantial clinical improvement of warts and molluscum (31). In 
contrast to the rapid expansion of gene-corrected T-cells in SCID-X1 infants following gene 
therapy, the T-cell marking in adult P1 and P2 increased slowly.  Prior to gene therapy, P1 and P2 
lacked donor stem cells and, together with the absence of TRECs, this suggests that circulating T-
cells were from a long-lived thymic population. The number of gene-corrected autologous cells 
continues to out-compete donor T-cells as indicated by the T-cell chimerism assays, and the 
increase in TRECS indicate the presence of at least some residual thymic function. Longer-term 
follow-up of similarly treated, but younger SCID-X1 patients will shed light on the relative 
importance of a more preserved thymus. Of note, the increase of all lineages (T-, B- and NK-
cells) continues steadily and stable CD34+ cell VCN even at 3 years post-therapy (in P1) and 
stable CD34+ gene marking (with 0.12 VCN in CD34+ at 1yr), demonstrating the persistence of 
lentivector-corrected hematopoietic stem cells. 
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Quantitative ddPCR surveillance of specific clones revealed dynamic fluctuations in clonal 
contribution such as integrations near PIM1, TNFSF12, and HMGA2; PIM1 transiently 
exceeded 20% of marked T­cells but less than 4% of the total lineage. Importantly, these 
clones decreased spontaneously over time. The integration profile in the patients is likely 
shaped by two major factors: firstly, the vector-preferred integration pattern at initial 
transduction, and secondly, selective expansion in vivo. Most of the CIS identified in our 
study and in previous studies simply reflect the initial integration preference of the 
lentivector, with no significant enrichment in vivo of any of the top CIS. Using a large in 
vitro CD34 integration dataset as a reference baseline of input clones, in vivo clonal 
expansion determined by fold increase over in vitro sample revealed in vivo expansion of 
HMGA2, previously described in β-thalassemia lentiviral gene therapy trial(29). Multiple 
independent integration sites in the HMG2A gene were found in both P1 and P2, but unlike 
the single HMGA2 restricted to the myeloid lineage in the b-thalassemia trial, the HMGA2 
clones in P1 and P2 were present in all cell lineages (myeloid, T-, B- and NK-cells), 
suggesting the growth advantage occurred in stem cells.  Furthermore, overexpression of the 
truncated HMGA2 gene selectively occurred in erythroblasts but remained undetectable in 
granulocytes-monocytes despite presence of the same clone at a greater frequency (29).  This 
suggests that the transcription of HMGA2 gene is under tight regulation, with variable 
expression in specific cell types at specific time points. We hypothesize that the integrations 
in this study found in the HMGA2 intron 3 provides some growth advantage of host cells 
transiently by production of the more stable truncated protein at a certain time point, but 
HMGA2 gene remains under the control and regulation of its native promoters, and can be 
turned off during the natural cell cycle or cell differentiation, which accounts for the absence 
of over-expression in P1 and P2 cells. The endogenous expression control for HMGA2 gene 
likely limits the growth expansion influence from the HMGA2 integration clones. Ongoing 
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monitoring of HMGA2 and other integration sites will shed further light on this.  
 
Since SCID-X1 is a rare disease, a limitation of this study is the small number of patients 
treated. Furthermore, all patients have received prior haplo-identical stem cell transplant that 
resulted in varying degrees of immune reconstitution. Consequently, the study population is 
heterogenous with a range of complex underlying medical problems that may impact the 
results.  Although only the first 2 older patients have been observed up to 2-3years, early 
myeloid gene marking corresponds to B-cell gene marking and humoral immunity 
improvement, providing possible early indicators of outcome. Since vector-related 
mutagenesis did not appear until 3-4 years following gene therapy in the SCID-X1 infants 
(22), insertion-related mutagenesis cannot be definitively excluded although the diverse 
repertoire of integrations to date, and the absence of adverse events in the larger experience 
with LV-gene therapy in other diseases, is reassuring. Our results from the young adult 
patients suggest that LV­mediated gene therapy with reduced intensity conditioning is a 
promising approach for treatment of SCID­X1, including in older patients. Importantly, such 
interventions should be considered early to minimize irreversible organ damage from 
sub­optimal immune reconstitution, as T­cell reconstitution alone is clearly not sufficient to 
prevent or reverse progressive injury to lungs.  
 
Materials and Methods: 
This is a Phase I/II non-randomized clinical trial of ex vivo hematopoietic stem cell (HSC) 
gene transfer treatment for X-linked severe combined immunodeficiency (SCID-X1) using a 
self- inactivating, insulated lentiviral vector. The study is approved by the NIAID 
Institutional Regulatory Board (Clinical Protocol #11-I-0007). Institutional Biosafety 
Committee, Food and Drug Administration Agency (IND Drug# 15041) sponsored by NIAID 
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Regulatory Compliance and Human Subjects Protection Branch (RCHSPB). 
 
Lentiviral Vector 
The Cl20i4 EF1 hacOPT used in this clinical trial is the first use of lentivector produced by 
a previously described stable inducible lentivector-producer cell line GPRTG (15, 18). 
This is a Vesicular stomatitis virus G pseudotyped, 3rd generation SIN vector which uses a 
promoter fragment from the eukaryotic elongation factor alpha (EF1α) gene to express a 
codon-optimized human ac cDNA, and contains a 400-bp insulator fragment from the 
chicken β-globin locus within the self-inactivating long-terminal repeat. Large-scale 
clinical grade vector was manufactured at St Jude Children’s Research Hospital Vector 
Facility as previously published (Greene). Briefly, producer cells were cultured in WAVE 
Bioreactor system GE Healthcare Bioscience, Somerset, NJ), and harvests were filtered 
(Millipore, Billerica, MA), followed by a Mustang Q ion-exchange (Pall, Ann Arbor, MI), and a 
final concentration by diafiltration  (Millipore) (15).  Titers of the vector were 4.5-7.2 × 108 iu/ml. 
 
Autologous CD34+ hematopoietic stem cells collection and isolation 
Patients receive granulocyte colony stimulating factor (G-CSF) at 16mg/kg/day by 
subcutaneous injection for 5 consecutive days supplemented by Plerixafor (0.24mg/kg SQ 11 
hours prior to collection) (NIH protocol 94-I-0073) prior to apheresis at the NIH Clinical 
Center (22). The products were processed using FDA-approved Isolex immune anti-CD34 
magnetic bead system to isolate and enrich CD34+ cells by the NIH Cell Processing Facility, 
Department of Transfusion Medicine. Purified CD34+ HSCs were cryopreserved until gene 
therapy. 
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Transduction of CD34+ hematopoietic stem cells 
Ex vivo culture and transduction of the patient’s autologous CD34+ HSC with VSV-G 
pseudotyped CL20-4i-EF1α-hγc-OPT LV was performed and certified by the NIH 
Department of Transfusion Medicine Cell Processing Facility. Transduction involves thawing 
and suspension of patient CD34+ HSC in X-VIVO™10 serum-free growth medium 
(containing 1% human serum albumin plus cytokines (Stem cell factor 50-100 ng/mL; FLT-3 
ligand 50-100 ng/mL; Thrombopoietin 50-100 ng/mL; Interleukin-3 5 ng/mL). The cells were 
cultured in T175 tissue culture flasks coated with the recombinant fibronectin fragment known 
as Retronectin®, and exposed to lentivector for 6-8 hours each day for 2 consecutive days after 
an overnight pre-stimulation (Figure 1). Transduced CD34+ HSCs were washed and infused 
over <30 minutes at the end of culture after required safety testing and quality control testing. 
 
Conditioning Regimen 
A dose lower than that used in gRV-gene therapy for CGD (10mg/kg) (18) but higher than the 
dose used in gRV-gene therapy for ADA (4mg/kg) was chosen, at 6mg/kg given over 2 days. 
The busulfan levels are shown in Table 1, no dose adjustment was given. No T- or B-cell 
depleting agents were given. 
 
Clinical course 
No adverse events were noted with the infusion of the transduced CD34+ HSC cell product. 
The nadir for the expected busulfan-related effects of neutropenia and thrombocytopenia 
occurred at 2-3 weeks post-treatment (Fig. S2), and recovered without requiring any cellular 
support or intervention. Subjects were discharged home by 3-4 weeks following gene therapy. 
Three of the 5 patients developed febrile neutropenia that responded to empiric antimicrobial 
therapy.  An overview of the study implementation is shown in Table S1. 
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Laboratory Evaluation 
Cell lineage separation for gene marking and integration analysis 
Following polymorphonuclear granulocyte (PMN) separation using histopaque, the 
mononuclear leukocyte layer was fractionated by magnetic beads per manufacturer’s 
instructions (Dynal Beads, Invitrogen) (Supplementary Materials & Methods (SM&M)). 
The purity of the bead-sorted PMN from a healthy donor was analyzed (Fig. S3).  
 
B- cell preparations, flow cytometry phenotyping and functional analyses 
Immunophenotyping and cell sorting were performed on freshly processed peripheral blood 
mononuclear cells (PBMCs) or PBMCs that had been cryopreserved with the following anti- 
human mAbs: allophycocyanin (APC) anti-CD10, APC-H7 anti-CD20, and PE anti-IgG (BD 
Biosciences); peridinin chlorophyll protein-Cy5.5 (PerCP-Cy5-5) anti-CD19 and PE-Cy7 
anti- CD27 (eBioscience); FITC anti-CD21 (Beckman Coulter); VioBlue anti-IgA (Miltenyi 
Biotec) and Brilliant Violet 510 (BV510) anti-IgM. Cell sorting and immunophenotyping 
were performed on BD FACSAria II and BD FACSCanto II (BD Biosciences) flow 
cytometers, respectively. Analyses were performed with FlowJo Version 9.8.5 software 
(TreeStar). Memory B-cell responses to influenza were performed by ELISPOT as previously 
described (23) with B- cells isolated by negative magnetic bead-based selection (StemCell 
Technologies). Phenotyping of immune cells by flow cytometry was also performed by the 
CLIA-certified Clinical Immunology Laboratory/Department of Laboratory Medicine at the 
NIH Clinical Center. 
 
B-cell proliferation and class switching in response to IL-21/CD40L 
CFSE-based proliferation assays were performed on PBMCs of a healthy donor and P1 as 
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previously described (24), with following modifications. PBMCs were labeled with CFSE (0.5 
µM; Molecular Probes) and cultured with 50 ng/ml IL-21 (PeproTech) and 500 ng/ml CD40 
ligand (25). B cell proliferation was determined by CFSE dilution and immunoglobulin class- 
switch was measured by intracellular expression of IgG and IgM using flow cytometry. 
 
B-cell proliferation and class switching in response to IL-21/CD40L 
Peripheral blood mononuclear cells of a healthy donor and P1 were labeled with CFSE (0.5 
µM; Molecular Probes) and cultured with 50 ng/ml IL-21 (PeproTech) and 500 ng/ml CD40 
ligand (24-26). B cell proliferation was determined by CFSE dilution and immunoglobulin 
class-switch was measured by intracellular expression of IgG and IgM using flow cytometry. 
 
Peripheral blood CD34+ cell purification and expansion for vector copy number and 
integration site analyses 
Peripheral blood mononuclear cells were purified from non-mobilized peripheral blood by 
Ficoll separation (Lymphocyte Separation Medium; MP Biomedicals). CD34+ cells were 
isolated from PBMCs using MACS (Miltenyi Biotec) magnetic beads according to 
manufacturer’s protocol. CD34+ cells were expanded for 8 to 12 days in StemSpan II media 
(Stem Cell Technologies) supplemented with 100 ng/mL each of human stem cell factor, Flt3-
ligand, and thrombopoietin (PeproTech). DNA isolated using the DNeasy Blood and Tissue 
Kit (Qiagen). 
 
Quantitative determination of vector copy number by Digital Droplet PCR 
To measure the vector-carrying cells, we used a Digital Droplet PCR (ddPCR, BioRad, 
Hercules, CA) assay. The ddPCR assay allows the measurement of absolute copy number 
without using standard curve. The vector specific primers and probes are HIV- F(5’CTG 
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TTG TGT GAC TCT GGT AAC T3’), HIV-R(5’TTC GCT TTC AAG TCC CTG TT3’), HIV- 
probe(5'- /56-FAM/AAA TCT CTA/ZEN/GCA GTG GCG CCC G /3IABkFQ/ -3'). We 
multiplexed a reference gene assay for cell counts in the same reaction (MKL2-F, 5’AGA TCA 
GAA GGG TGA GAA GAA TG3’, MKL2-R, 5’GGA TGG TCT GGT AGT TGT AGT G3’, 
MKL2-probe, 5’-/56-HEX/TG TTC CTG C/ZEN/A ACT GCA GAT CCT GA/3IABkFQ/-3’).  
Cell number was calculated as a half of the MKL2 counts because each cell is diploid. Vector 
copy number was calculated as vectors/cell. 
 
Monitoring clonal expansion of specific integration site.  Top expanded clones identified 
by the VISA sequencing assay were followed up and monitored by specific ddPCR assay.    All 
of our ddPCR assays consist of a common LTR primer, a LTR probe, and a specific primer for 
genomic DNA junction (5LTR-Rev 5’CTG CAG GGA TCT TGT CTT CTT3’, 5LTRjunction-
probe, 5’/56-FAM/TGG AAG GGC/ZEN/TAA TTC ACT CCC A /3IABkFQ/3’, PIM1-5LTR 
primer: 5’TCC TAA CAT CCC CAC TGC AT3’, TNFSF12-5LTR primer: 5’ACA GTA AAG 
CAA GAG TGG GAT G3’; 3LTR-F CCC ACT GCT TAA GCC TCA ATA, 3LTRjunction-
probe, 5'- /56-FAM/AAG TAG TGT/ZEN/GTG CCC GTC TGT TGT/3IABkFQ/ -3', 
CDKN1A-3LTR primer: 5’GCA CGA AAT CAC TGC CAT ATT C3’ ). We multiplexed the 
integration site specific assay together with the MKL2 reference gene assay which measures cell 
counts in the same reaction. The use of ddPCR makes it possible to: 1) monitor the specific 
integration site accurately, 2) use limited amount of input DNA, 3) make monitoring of expanded 
clones easy over time and across many different cell lineages.  
 
Evaluation of insulator size in peripheral blood cells from P1 
Genomic DNA P1 was used for PCR amplification, using PCR primer sequences for the 5’ LTR 
were 5’-CTG GAA GGG CTA ATT CAC TC-3’ (P1) and 5’-TCG CGA TCT AAT TCT CC-3’ 
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(p2); and for the 3’ LTR were 5’-GCG GCC GCA TCG ATG CCG TAT AC-3’ (P3) and 5’-CTG 
CTA GAG ATT TTC CAC AC-3’ (P4). The expected size of the 5’ and 3’ LTR PCR fragments 
with the intact 400bp insulator element was 851bp and 791bp, respectively (The exact length of 
both LTRs are 649bp without insulator). The sequences of the two PCR fragments were 
confirmed by direct DNA sequencing of the PCR product. The smaller band (around 500bp) with 
the P1/P2 primer was TA cloned and sequenced, confirming a mispriming of P2 in the R region 
which resulted in the artifact, and that the 400bp insulator is intact.  
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Figure and Table Captions: 
Figure Legends: 
Figure 1. Immune cell gene marking and numbers after gene therapy.  
(A) Gene marking in sorted cell lineages as vector copy number (VCN) per genome 
following treatment in P1 (to 36 months) and P2 (to 24 months). 
(B) Early gene marking in first 6 months in myeloid and B-cells in P1-5. 
(C) Percent autologous (corrected) host cells as determined by RFLP assay of T-cell 
chimerism. 
(D) Immune cell numbers in P1 and P2 following treatment. 
 
Figure 2. Functional correction of T- and B-cells with SIN-LV gene therapy.  
(A) CD3 T-cell proliferative responses to indicated stimuli. 
(B) Emergence of transitional T1 B-cells (CD10++CD21lo) in P3 at 12 weeks, progressing to 
T2/3 B-cells (CD10+CD21hi) by 16 weeks post gene therapy. 
(C) Changes in B-cell subset profiles over time in P3. 
(D) Serum IgM and IgG over time in P1 and P2 post treatment.  Withdrawal of supplemental 
IgG is indicated by the arrow.  Dotted lines indicate respective normal reference ranges. 
(E) Early increases in IgM, comparing P1-5.  
(F) A summary of vector copy number in flow-sorted T1, T2/3, Naive B-cells compared to 
CD3 T cells from P3, P4 and P5. 
Figure 3. Restoration of B-cell signaling and specific antibody production 
(A) B-cell responses to IL-21 and CD40L stimulation. Peripheral blood mononuclear cells 
from P1 (bottom) and a healthy control (HC, top) were stained with CFSE and stimulated 
with IL-21 and CD40 ligand (CD40L). Gated CD3-CD19+ B-cells that have undergone 
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division are shown in left upper area showing CD27+ (column 1), and IgG+ (column 2), 
and IgM+ (column 3) expressing B-cells. 
(B) ELISPOT of P1 B-cells before and after vaccination. Numbers of Ig antibody secreting 
cells (ASC) (left), influenza-specific ASC per 106 B cells, and influenza-specific as a 
fraction of total Ig ASCs (right) detected by ELISPOT of peripheral blood B-cells from 
P1 before and after influenza vaccination to determine memory B-cell responses. 
Figure 4. Clinical progress following gene therapy.  
(A) Photographs demonstrating Human Papilloma Virus warts (top) and molluscum 
contagiosum on P2 (bottom) before and 15 months after gene therapy as indicated. 
(B) Serial serum albumin for P1-P5 following gene therapy.  (Upper and lower reference 
ranges are indicated by dotted lines. 
(C) Body mass measurements for P1-P5 following treatment. 
 
Figure 5. Vector Integration site analysis (VISA). 
(A)  Total unique integration sites, shown in proportion to their representation of the total 
diversity in P1 and P2 to 30 and 24 months respectively (left). Clonal composition for 
sorted cell lineages for P1 and P2 (right). Each horizontal bar represents clonal 
frequency, from most abundant on the top. The number of unique clones in the top 50% 
of the cells, UC50, is listed above each sample.  
(B) Serial quantitative ddPCR tracking of the 4 most frequent clones (TNFSF12, TNFSF12-
TNFSF13, chr 6 and PIM1) in P2 is shown as a percentage of vector-marked cells (left), 
or of total cells in each lineage (right). 
(C) Schematic of unique integrations in HMGA2 in P1 and P2.  Most clones (enumerated 
next to arrow) are in the same orientation as the gene (blue), with a few in the reverse 
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orientation (red). Clones are seen in all lineages; CD34, CD14, CD19, NK and PMN, and 
CD3 (summarized below). 
 
Figure 6.  
Circular projection of the human genome with integration sites from P1 and P2 (in vivo 
orange, red), in vitro lentivector-transduced CD34 cells (green), and in vitro mγRV-
transduced CD34 cells (red). The top 100 target genes (in vitro) are listed on the outside 
with top 10 target genes (in vitro) in bold. 
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Tables:  
Table 1 Patient characteristics and treatment. 
All patients received allogeneic stem cell transplant (HSCT) from haploidentical (haplo) parent 
donor once or repeated (booster). SQ, subcutaneous injection, CFU, colony forming units; TCR, 
T-cell receptor; PLE, protein-losing enteropathy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
P1# P2# P3# P4# P5#
IL2RG 
mutation!
823T>G! 447 delA! 923C>A! c341G>A! 31T>A!
Age (yrs)! 23! 22! 7! 15! 10!
Prior HSCT! Haplo; booster ! Haplo! Haplo:  booster! Haplo! Haplo; 
booster!
Immuno-
phenotype!
! T, B, NK! ! B, NK! ! T, B, NK! !T, B, NK! !T, B, NK!
Medical 
problems!
!
Norovirus, 
infections!
PLE, IVIG!
Norovirus, infections, 
IVIG,Warts, 
molluscum, 
bronchiectasis, 
bronchiolitis 
obliterans!
Norovirus, 
infections, !
PLE, IVIG, 
bronchiectasis, 
growth failure!
Norovirus, 
infections, PLE, 
IVIG, 
bronchiectasis!
Norovirus!
PLE, IVIG,!
Molluscum, 
bronchiectasi
s!
Busulfan AUC 
(min*umol/L)!
3603.1! 4528.9! 2519.6! 4523.6! 3096.6!
CD34+ Cells 
infused (x106/
kg)!
18! 16! 20.4! 21.7! 25!
Bulk CD34 In 
vitro-CFU (%)!
27! 17! 22! 57.7! 36.1!
Follow-up 
(months)!
36! 24! 6! 3! 3!
Current status! Cleared 
norovirus, off 
IVIG!
Cleared norovirus, off 
IgG supplement, fatal 
bronchial bleed!
stable! stable! stable!
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